Observations highlighted that these NPs increased the antitumor effect and drug accumulation in the tumor, significantly disrupting tumor growth, according to Fig. 3B. Compared to free DTX, targeted PLGAs were used to successfully transport the drug to both triple-negative and HER2+ breast cancer cells in clinical models, halting tumor growth. This evidence concerns the gene ERBB2 and breast carcinoma.